1. The Diabetic Cardiac Fibroblast: Mechanisms Underlying Phenotype and Function
   Scott P. Levick et al, 2020, International Journal of Molecular Sciences CrossRef
2. Efficacy of trimetazidine – an inhibitor of free fatty acids oxidation in the treatment of patients with stable angina pectoris and heart failure
   M. G. Bubnova et al, 2021, Kardiologiia CrossRef
3. Trimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoter
   Hong-yang Shu et al, 2022, Acta Pharmacologica Sinica CrossRef
4. Trimetazidine to Reduce Myocardial Fibrosis—Competing Interests with SGLT2 Inhibitors?
   Tyler B. Moran et al, 2023, Cardiovascular Drugs and Therapy CrossRef
5. Trimetazidine in Heart Failure
   Hongyang Shu et al, 2021, Frontiers in Pharmacology CrossRef
6. Protective Mechanism of Trimetazidine in Myocardial Cells in Myocardial Infarction Rats through ERK Signaling Pathway
   Zhenjun Wu et al, 2021, BioMed Research International CrossRef
7. miR-30a-5p inhibits the proliferation and collagen formation of cardiac fibroblasts in diabetic cardiomyopathy
   Xiao-xu Yang et al, 2022, Canadian Journal of Physiology and Pharmacology CrossRef
8. Communication Between Cardiomyocytes and Fibroblasts During Cardiac Ischemia/Reperfusion and Remodeling: Roles of TGF-β, CTGF, the Renin Angiotensin Axis, and Non-coding RNA Molecules
   Raúl Flores-Vergara et al, 2021, Frontiers in Physiology CrossRef